drugset
drugset / Trial / NCT04765098

Tamoxifen Versus Etoposide After First Recurrence in GBM Patients

NCT04765098 ↗

Phase 2 Recruiting 60 enrolled AHS Cancer Control Alberta
RandomizedParallel-groupOpen-labelTreatment

Summary

The investigator propose a single-center randomized phase II controlled study designed to compare the management of first recurrence of GBM using etoposide versus tamoxifen.

Timeline

Start
2022-01-28
Primary completion
2026-12
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Etoposide Small molecule 50 mg/m2 —
Subject Tamoxifen Small molecule 100 mg —

Indications

glioblastoma